Touchlight is a manufacturer of high-purity, cell-free DNA using its proprietary enzymatic dbDNA technology to support the development of genetic medicines.
Touchlight has raised €107M across 2 funding rounds from 3 investors, most recently a Grant round in Dec 2022. Based in London, UK; active in Healthtech. Data as of 21 Sept 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-12-02 | Grant | — | The Bill & Melinda Gates Foundation | View deal → |
| 2021-09-20 | Other | €107M | Bridford Investments Limited,Novator Partners | View deal → |
